Deferoxamine in intracerebral hemorrhage: Systematic review and meta-analysis

Clin Neurol Neurosurg. 2023 Apr:227:107634. doi: 10.1016/j.clineuro.2023.107634. Epub 2023 Feb 20.


Background: Intracerebral hemorrhage (ICH) is a stroke with a high morbidity and mortality rate. Deferoxamine (DFX) is thought to be effective in treating Intracerebral Hemorrhage. In our study, we performed a meta-analysis to evaluate the treatment effects of DFX.

Methods: We systematically searched PubMed, Embase, Web of Science, the Cochrane Central Register of Controlled Trials, and Chinese Biomedical Literature Database in Jan 2022 for studies on DFX for ICH patients. Outcome measures included relative hematoma volume, relative edema volume, good neurological functional outcome and adverse events. Odds risk (OR) and weighted mean difference (WMD) were used to evaluate clinical outcomes.

Results: After searching 636 articles, 4 RCTs, 2 NRCTs, and 1cohort study were included. We found that DFX was effective in hematoma absorption on day 7 after onset, but the difference was not significant on day 14. DFX could suppress edema expansion on days 3, 7, and 14 after onset. DFX did not contribute to better outcomes after 3 and 6 months when used the modified Rankin Scale and the Glasgow Outcome Scale to evaluate neurological prognosis. The pooled results showed no statistically significant difference in Serious adverse events between the experimental and control groups.

Conclusions: DFX could limit edema expansion on days 3, 7, and 14 after commencement and facilitate hematoma absorption at week 1 without significantly increasing the risk of adverse events, but it did not improve neurological prognosis.

Keywords: Deferoxamine; Intracerebral Hemorrhage; Medical treatment; Meta-analysis; Safety.

Publication types

  • Meta-Analysis
  • Systematic Review
  • Review

MeSH terms

  • Cerebral Hemorrhage / drug therapy
  • Deferoxamine* / adverse effects
  • Hematoma / drug therapy
  • Humans
  • Siderophores / pharmacology
  • Siderophores / therapeutic use
  • Stroke* / drug therapy


  • Deferoxamine
  • Siderophores